- Home
- GSL vs COGT Comparison
GSL vs COGT Comparison
Compare GSL & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- COGT
- Stock Information
- Founded
- GSL 2007
- COGT 2014
- Country
- GSL Greece
- COGT United States
- Employees
- GSL N/A
- COGT N/A
- Industry
- GSL Marine Transportation
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- GSL Consumer Discretionary
- COGT Health Care
- Exchange
- GSL Nasdaq
- COGT Nasdaq
- Market Cap
- GSL 945.2M
- COGT 817.5M
- IPO Year
- GSL 2006
- COGT 2018
- Fundamental
- Price
- GSL $27.95
- COGT $11.19
- Analyst Decision
- GSL Strong Buy
- COGT Strong Buy
- Analyst Count
- GSL 1
- COGT 9
- Target Price
- GSL $30.00
- COGT $19.38
- AVG Volume (30 Days)
- GSL 342.4K
- COGT 4.7M
- Earning Date
- GSL 08-04-2025
- COGT 08-05-2025
- Dividend Yield
- GSL 7.53%
- COGT N/A
- EPS Growth
- GSL 20.64
- COGT N/A
- EPS
- GSL 10.54
- COGT N/A
- Revenue
- GSL $715,232,000.00
- COGT N/A
- Revenue This Year
- GSL $3.22
- COGT N/A
- Revenue Next Year
- GSL N/A
- COGT N/A
- P/E Ratio
- GSL $2.62
- COGT N/A
- Revenue Growth
- GSL 3.83
- COGT N/A
- 52 Week Low
- GSL $17.73
- COGT $3.72
- 52 Week High
- GSL $28.08
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- GSL 69.67
- COGT 87.74
- Support Level
- GSL $26.80
- COGT $7.07
- Resistance Level
- GSL $27.60
- COGT $10.23
- Average True Range (ATR)
- GSL 0.57
- COGT 0.66
- MACD
- GSL 0.06
- COGT 0.37
- Stochastic Oscillator
- GSL 99.61
- COGT 99.89
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.